a biopharmaceutical company
Industry Biotechnology
A.I.dvisor detected a bullish Broadening Wedge Descending pattern for INVA stock. This pattern was detected on September 23, 2026 . The odds of reaching the target price are 6.
The Broadening Wedge Descending pattern forms when the price of a security makes lower lows (1, 3, 5) and lower highs (2, 4), forming a downtrend.
Consider buying a security or call option at the upward breakout price level.
The Stochastic Oscillator for INVA moved into oversold territory on September 25, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
The Momentum Indicator moved above the 0 level on September 24, 2026. You may want to consider a long position or call options on INVA as a result. In 43 of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 58%.
Following a +2.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where INVA advanced for three days, in 189 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
INVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Moving Average Convergence Divergence Histogram (MACD) for INVA turned negative on September 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 28 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.
The 50-day moving average for INVA moved below the 200-day moving average on August 24, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for INVA entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. INVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.215) is normal, around the industry mean (26.453). P/E Ratio (4.812) is within average values for comparable stocks, (42.231). Projected Growth (PEG Ratio) (3.100) is also within normal values, averaging (9.058). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (4.092) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.